125 related articles for article (PubMed ID: 26561567)
21. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway.
Sulpice E; Bryckaert M; Lacour J; Contreres JO; Tobelem G
Blood; 2002 Nov; 100(9):3087-94. PubMed ID: 12384403
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
[TBL] [Abstract][Full Text] [Related]
23. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
[TBL] [Abstract][Full Text] [Related]
24. Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.
Jane EP; Premkumar DR; Addo-Yobo SO; Pollack IF
J Pharmacol Exp Ther; 2009 Oct; 331(1):327-37. PubMed ID: 19622715
[TBL] [Abstract][Full Text] [Related]
25. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
[TBL] [Abstract][Full Text] [Related]
27. 4-Phenybutyric acid promotes gastric cancer cell migration via histone deacetylase inhibition-mediated HER3/HER4 up-regulation.
Shi X; Zheng C; Li C; Hou K; Wang X; Yang Z; Liu C; Liu Y; Che X; Qu X
Cell Biol Int; 2018 Jan; 42(1):53-62. PubMed ID: 28851073
[TBL] [Abstract][Full Text] [Related]
28. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
[TBL] [Abstract][Full Text] [Related]
29. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.
Vettraino M; Manerba M; Govoni M; Di Stefano G
Anticancer Drugs; 2013 Sep; 24(8):862-70. PubMed ID: 23797802
[TBL] [Abstract][Full Text] [Related]
30. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
[TBL] [Abstract][Full Text] [Related]
31. Cathepsin S Activity Controls Injury-Related Vascular Repair in Mice via the TLR2-Mediated p38MAPK and PI3K-Akt/p-HDAC6 Signaling Pathway.
Wu H; Cheng XW; Hu L; Takeshita K; Hu C; Du Q; Li X; Zhu E; Huang Z; Yisireyili M; Zhao G; Piao L; Inoue A; Jiang H; Lei Y; Zhang X; Liu S; Dai Q; Kuzuya M; Shi GP; Murohara T
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1549-57. PubMed ID: 27365406
[TBL] [Abstract][Full Text] [Related]
32. Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.
Okabe S; Tanaka Y; Moriyama M; Gotoh A
Cancer Chemother Pharmacol; 2020 Feb; 85(2):401-412. PubMed ID: 31901955
[TBL] [Abstract][Full Text] [Related]
33. Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax.
Somervaille TC; Linch DC; Khwaja A
Blood; 2001 Sep; 98(5):1374-81. PubMed ID: 11520785
[TBL] [Abstract][Full Text] [Related]
34. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
Wozniak MB; Villuendas R; Bischoff JR; Aparicio CB; MartÃnez Leal JF; de La Cueva P; Rodriguez ME; Herreros B; Martin-Perez D; Longo MI; Herrera M; Piris MA; Ortiz-Romero PL
Haematologica; 2010 Apr; 95(4):613-21. PubMed ID: 20133897
[TBL] [Abstract][Full Text] [Related]
35. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.
Karam AK; Santiskulvong C; Fekete M; Zabih S; Eng C; Dorigo O
Cytoskeleton (Hoboken); 2010 Aug; 67(8):535-44. PubMed ID: 20607860
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
Yu XD; Wang SY; Chen GA; Hou CM; Zhao M; Hong JA; Nguyen DM; Schrump DS
Cancer J; 2007; 13(2):105-13. PubMed ID: 17476138
[TBL] [Abstract][Full Text] [Related]
38. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
Lai JP; Sandhu DS; Yu C; Moser CD; Hu C; Shire AM; Aderca I; Murphy LM; Adjei AA; Sanderson S; Roberts LR
Liver Int; 2010 Nov; 30(10):1522-8. PubMed ID: 21040406
[TBL] [Abstract][Full Text] [Related]
39. Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells.
Xia C; He Z; Cai Y; Liang S
Eur J Pharmacol; 2020 May; 875():173057. PubMed ID: 32135122
[TBL] [Abstract][Full Text] [Related]
40. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
Chen E; Pei R
J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
